Stuart Walter Peltz - Jan 5, 2023 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
4
Date filed
1/9/2023, 03:51 PM
Previous filing
Jun 9, 2022
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +53K +43.99% $0.00 173K Jan 5, 2023 Direct F1
transaction PTCT Common Stock Award $0 +18K +46.36% $0.00 56.8K Jan 5, 2023 By Spouse F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +133K $0.00 133K Jan 5, 2023 Common Stock 133K $39.42 Direct F3
transaction PTCT Stock Option (Right to Buy) Award $0 +45K $0.00 45K Jan 5, 2023 Common Stock 45K $39.42 By Spouse F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on January 5, 2023 that vest in four equal installments over four years, commencing on January 5, 2024.
F2 Includes 293 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2022 and 298 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2022.
F3 This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.